Abstract
Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients.
Keywords: COVID-19; Hematologic Malignancies; anti-spike igG; mRNA vaccine.
All Keywords
【저자키워드】 COVID-19, mRNA vaccine., anti-Spike IgG, hematologic malignancies, 【초록키워드】 antibodies, IgG, vaccination, spike, antibody, mRNA vaccine, Immunocompromised patients, COVID-19 infection, Patient, Critical, Anti-spike, Hematologic malignancy, Post-vaccine, highlight, semi-quantitative, 【제목키워드】 immunogenicity, report, Sery,
【저자키워드】 COVID-19, mRNA vaccine., anti-Spike IgG, hematologic malignancies, 【초록키워드】 antibodies, IgG, vaccination, spike, antibody, mRNA vaccine, Immunocompromised patients, COVID-19 infection, Patient, Critical, Anti-spike, Hematologic malignancy, Post-vaccine, highlight, semi-quantitative, 【제목키워드】 immunogenicity, report, Sery,
{{{ 추상적인 }}}
혈액암 환자에서 코로나19 2회 접종 시리즈의 면역원성에 대한 데이터는 제한적이며 현재 지침에서는 백신 접종 후 항체에 대한 일상적인 모니터링을 권장하지 않습니다. 그러나 우리는 백신 접종 후 6개월 후에 심각하거나 치명적인 COVID-19 감염이 발생한 3명의 환자에 대해 설명합니다. 이것은 특히 면역 저하 환자에서 백신 접종 후 반정량적 항체인 COVID-19 IgG 스파이크의 일상적인 테스트의 중요성을 강조합니다.
{{ 키워드: }} 코로나19; 혈액암; 스파이크 방지 igG; mRNA 백신.